Search
Pulmonary Fibrosis Clinical Trials in Phoenix, AZ
A listing of 7 Pulmonary Fibrosis clinical trials in Phoenix, AZ actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 7 of 7
The city of Phoenix, Arizona, currently has 7 active clinical trials seeking participants for Pulmonary Fibrosis research studies.
Featured Trial
Healthy Participants Needed (Colonoscopy + Cancer Screening)
Recruiting
Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
Conditions:
Healthy
Healthy Volunteers
Healthy Subjects
Healthy Volunteer
Healthy Participants
Featured Trial
COVID Vaccine Age 50-64 Study (Up to $710 Total Compensation)
Recruiting
Multiple COVID-19 investigational vaccine studies are now enrolling participants (Age 50-64), with appointments available. Participants who qualify may receive up to $710 in total compensation.
If eligible, participants may be matched to one of the current COVID-19 vaccine studies. Should you express interest, the study team will contact you directly to provide further details and answer any questions about study procedures, time commitment, potential risks/benefits, and compensation.
If eligible, participants may be matched to one of the current COVID-19 vaccine studies. Should you express interest, the study team will contact you directly to provide further details and answer any questions about study procedures, time commitment, potential risks/benefits, and compensation.
Conditions:
COVID Vaccine (Age 50-64)
COVID
COVID-19
COVID19
COVID 19
Featured Trial
Vaccine (18+) Clinical Study
Recruiting
We are seeking healthy individuals aged 18 and above who are interested in participating in a vaccine clinical trial.
Conditions:
Vaccine (18+)
Healthy
Healthy Individuals
Healthy Volunteers
Healthy Subjects
Featured Trial
Vaccine (65+) Clinical Study
Recruiting
We are seeking healthy participants aged 65 and above who are interested in participating in a vaccine clinical trial.
Conditions:
Vaccine (65+)
Healthy
Older Adults
Seniors
Healthy Volunteers
Featured Trial
Adult Vaccine Clinical Trial
Recruiting
Looking to boost your immunity?
You may be interested in participating in an Adult Vaccine Clinical Trial.
The Adult Vaccine Research Studies are looking for adults to evaluate the effectiveness of a potential vaccine.
You may be interested in participating in an Adult Vaccine Clinical Trial.
The Adult Vaccine Research Studies are looking for adults to evaluate the effectiveness of a potential vaccine.
Conditions:
Healthy
Healthy Volunteers
Healthy Subjects
Healthy Volunteer
Healthy Participants
Featured Trial
Healthy Clinical Study
Recruiting
A clinical study for healthy individuals.
Conditions:
Healthy
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
08/20/2025
Locations: Local Institution - 0416, Phoenix, Arizona +1 locations
Conditions: Progressive Pulmonary Fibrosis
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
Recruiting
Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: Norton Thoracic Institute, Phoenix, Arizona
Conditions: Progressive Pulmonary Fibrosis, Interstitial Lung Disease
A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease
Recruiting
The main purpose of the study is to evaluate the efficacy of vixarelimab compared with placebo on lung function in participants with idiopathic pulmonary fibrosis (IPF) and in participants with systemic sclerosis-associated interstitial lung disease (SSc-ILD). Participants who complete 52-weeks of treatment in the Double-blind Treatment (DBT) period can choose to enroll in the optional Open-label Extension (OLE) period to receive treatment with vixarelimab for another 52 weeks.
Cohort 1 has com... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
08/08/2025
Locations: Banner University Medicine Lung Institute, Phoenix, Arizona
Conditions: Idiopathic Pulmonary Fibrosis, Systemic Sclerosis With Lung Involvement
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
08/07/2025
Locations: St. Joseph's Hospital and Medical Center, Phoenix, Arizona
Conditions: Idiopathic Pulmonary Fibrosis
WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Recruiting
A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF)
Gender:
ALL
Ages:
40 years and above
Trial Updated:
08/05/2025
Locations: WISPer site in Phoenix, AZ, Phoenix, Arizona
Conditions: Idiopathic Pulmonary Fibrosis
Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF
Recruiting
This is a randomized, double-blinded, placebo-controlled multicenter study to evaluate the safety and efficacy of DWN12088 in patients with Idiopathic Pulmonary Fibrosis.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
07/31/2025
Locations: Dignity Health Norton Thoracic Institute, Phoenix, Arizona
Conditions: Idiopathic Pulmonary Fibrosis
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
Recruiting
A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus placebo on top of standard of care in participants with PPF over 52 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/23/2025
Locations: Pulmonary Associates, PA, Phoenix, Arizona
Conditions: Progressive Pulmonary Fibrosis
1 - 7 of 7
